Published in Eur J Cancer on August 27, 2008
Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer (2009) 1.93
Evaluation of a home-based colorectal cancer screening intervention in a rural state. J Rural Health (2013) 0.99
Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health (2014) 0.99
Uptake and positive predictive value of fecal occult blood tests: A randomized controlled trial. Prev Med (2013) 0.97
Increasing colorectal cancer screening in an overdue population: participation and cost impacts of adding telephone calls to a FIT mailing program. J Community Health (2014) 0.94
Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study. BMC Gastroenterol (2012) 0.91
Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy. Am J Gastroenterol (2015) 0.89
Cost-effectiveness of colorectal cancer screening - an overview. Best Pract Res Clin Gastroenterol (2010) 0.88
Similar fecal immunochemical test results in screening and referral colorectal cancer. World J Gastroenterol (2012) 0.86
Validity of fecal occult blood test in the national cancer screening program, Korea. PLoS One (2013) 0.84
Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use. Eur J Gastroenterol Hepatol (2015) 0.83
Perspectives of colorectal cancer screening in Germany 2009. World J Gastrointest Endosc (2009) 0.81
Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy. J Med Screen (2014) 0.81
Prevention, screening and treatment of colorectal cancer: a global and regional generalized cost effectiveness analysis. Cost Eff Resour Alloc (2010) 0.80
Progress and challenges in colorectal cancer screening. Gastroenterol Res Pract (2012) 0.79
The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings. Clin Exp Gastroenterol (2015) 0.78
Fecal immunochemical test for colorectal cancer from a prospective cohort with 513,283 individuals: Providing detailed number needed to scope (NNS) before colonoscopy. Medicine (Baltimore) (2016) 0.75
The effectiveness of FOBT vs. FIT: A meta-analysis on colorectal cancer screening test. Med J Islam Repub Iran (2016) 0.75
Cancer: What is the best screening test for colorectal cancer? Nat Rev Gastroenterol Hepatol (2010) 0.75
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Epidemiology and management of liver metastases from colorectal cancer. Ann Surg (2006) 3.37
Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res (2008) 2.83
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology (2013) 2.78
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer (2008) 2.68
Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology (2004) 2.63
Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol (2008) 1.85
Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut (2010) 1.50
How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer (2002) 1.50
Survival from rare cancer in adults: a population-based study. Lancet Oncol (2006) 1.49
Who is implicated in the care of digestive cancers? A population-based study over a 25-year period. Gastroenterol Clin Biol (2006) 1.48
Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology (2007) 1.44
Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut (2011) 1.42
Trends in incidence and management of esophageal adenocarcinoma in a well-defined population. Gastroenterol Clin Biol (2005) 1.40
Patterns of adjuvant chemotherapy for stage II and III colon cancer in France and Italy. Dig Liver Dis (2013) 1.39
Clinical value of mitochondrial mutations in colorectal cancer. J Clin Oncol (2005) 1.33
Transcatheter arterial embolization of splenic artery aneurysms and pseudoaneurysms: short- and long-term results. Ann Vasc Surg (2008) 1.23
Patterns of care for European colorectal cancer patients diagnosed 1996-1998: a EUROCARE high resolution study. Acta Oncol (2010) 1.23
Refractory bleeding from gastroduodenal ulcers: arterial embolization in high-operative-risk patients. J Clin Gastroenterol (2008) 1.16
Improvement in colorectal cancer survival: a population-based study. Eur J Cancer (2005) 1.16
A relative survival regression model using B-spline functions to model non-proportional hazards. Stat Med (2003) 1.14
Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open (2013) 1.10
Place of multidisciplinary consulting meetings and clinical trials in the management of colorectal cancer in France in 2000. Gastroenterol Clin Biol (2007) 1.08
Hepato-gastroenterologists and oncologists are complementary in the management of digestive cancers. Dig Liver Dis (2011) 1.07
High dietary iron and copper and risk of colorectal cancer: a case-control study in Burgundy, France. Nutr Cancer (2004) 1.05
Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis (2005) 1.03
Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol (2006) 1.02
Explaining gastric cancer survival differences among European countries. Int J Cancer (2004) 1.00
Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method. BMC Cancer (2012) 0.99
Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: a French population-based study. J Am Geriatr Soc (2011) 0.99
Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur J Health Econ (2007) 0.98
Survival from rectal and anal cancers in England and Wales, 1986-2001. Eur J Cancer (2006) 0.96
European Commission's proposal for a council recommendation on cancer screening. BMJ (2003) 0.96
Trends in the incidence of digestive cancers in France between 1980 and 2005 and projections for the year 2010. Eur J Cancer Prev (2011) 0.96
Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis (2013) 0.95
Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer (2006) 0.94
Trends in frequency and management of obstructing colorectal cancers in a well-defined population. Dis Colon Rectum (2007) 0.93
Treatment and prognosis of hepatocellular carcinoma: a population based study in France. J Surg Oncol (2008) 0.93
Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study. Cancer (2008) 0.93
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol (2008) 0.93
Conditional relative survival of cancer patients and conditional probability of death: a French National Database analysis. Cancer (2009) 0.92
What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer (2010) 0.92
Which patients with colorectal cancer are followed up by general practitioners? A population-based study. Eur J Cancer Prev (2007) 0.91
Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008). Inflamm Bowel Dis (2012) 0.90
Fractions of cardiovascular diseases, mental disorders, and musculoskeletal disorders attributable to job strain. Int Arch Occup Environ Health (2011) 0.90
Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol (2004) 0.88
The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. Eur J Cancer (2008) 0.87
Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Technol Assess Health Care (2004) 0.87
Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med (2005) 0.86
Rising incidence of pancreatic cancer in France. Pancreas (2010) 0.86
Trends in incidence of digestive cancers in France. Eur J Cancer Prev (2008) 0.86
Trends in colorectal cancer incidence: a period and birth-cohort analysis in a well-defined French population. BMC Cancer (2011) 0.86
Trends in the incidence and management of biliary tract cancer: a French population-based study. J Hepatol (2010) 0.86
Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test. Int J Technol Assess Health Care (2010) 0.84
Regional variations in management of rectal cancer in France. Gastroenterol Clin Biol (2004) 0.83
Screening for colorectal cancer with immunochemical faecal occult blood tests. Dig Liver Dis (2012) 0.83
Patterns of surveillance practices after curative surgery for colorectal cancer in a French population. Dis Colon Rectum (2005) 0.83
[Recent data on the epidemiology of esophageal cancer]. Gastroenterol Clin Biol (2005) 0.83
Incidence, patterns of failure, and prognosis of perforated colorectal cancers in a well-defined population. Dis Colon Rectum (2009) 0.82
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. Eur Radiol (2011) 0.82
Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. Pathol Res Pract (2003) 0.82
Incidence and survival in late liver metastases of colorectal cancer. J Gastroenterol Hepatol (2015) 0.81
Evaluation of the management of rectal cancers before and after the consensus conference in France. Eur J Gastroenterol Hepatol (2004) 0.81
Late outcomes of colorectal cancer treatment: a FECS-EUROCARE study. J Cancer Surviv (2007) 0.81
A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol (2010) 0.81
Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. Ann Surg Oncol (2014) 0.81
Mitochondrial D310 mutations in colorectal adenomas: an early but not causative genetic event during colorectal carcinogenesis. Int J Cancer (2008) 0.81
[Epidemiology and screening of colorectal cancer]. Rev Prat (2004) 0.81
Does the availability of positron emission tomography modify diagnostic strategies for solitary pulmonary nodules? An observational study in France. BMC Cancer (2009) 0.80
Management of rectal cancer in France in a well-defined population. Eur J Gastroenterol Hepatol (2014) 0.80
[Genetic pathways in colorectal cancer: interest for the pathologist]. Ann Pathol (2002) 0.79
Trends in the management of gastric cancer over a 32-year period: a French population-based study. Gastric Cancer (2014) 0.79
Tobacco use and associations of beta-carotene and vitamin intakes with colorectal adenoma risk. J Nutr (2005) 0.79
How do gastroenterologists follow patients with colorectal cancer after curative surgical resection? A three-year population-based study. Gastroenterol Clin Biol (2007) 0.79
Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colorectal cancer screening. Eur J Cancer Prev (2016) 0.78
Foods as risk factors for colorectal adenomas: a case-control study in Burgundy (France). Nutr Cancer (2002) 0.78
Prevalence of patients with colorectal cancer requiring follow-up or active treatment. Eur J Cancer (2009) 0.77
Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. Dig Liver Dis (2011) 0.77
[Epidemiology and screening of colon cancer]. Rev Prat (2010) 0.77
Rural-urban inequalities in detection rates of colorectal tumours in the population. Dig Liver Dis (2011) 0.77
Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience. Cardiovasc Intervent Radiol (2012) 0.77
Faecal occult blood screening for colorectal cancer in Serbia: a pilot study. Eur J Cancer Prev (2017) 0.76